Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin

1 Min Read

(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG’s skin and lung cancer drug Proleukin for a total of $210 million (163 million pounds), including some future payments.

The deal will give Clinigen global rights to the drug and the company expects the deal to add to its profitability this year, and forecast a growth in adjusted EBITDA for the six months ended December.

(This story corrects headline and paras 1 and 2 to clarify that deal has been agreed but not yet completed).

Reporting by Pushkala Aripaka in Bengaluru; Editing by Gopakumar Warrier